Program
Rabeprazole
Also written as “rabeprazole”, “rabeprazole sodium” and “E3810”.
Its studies are mostly in Gastroesophageal Reflux · Esophagitis, Peptic · Gastrointestinal Diseases · Stomach Ulcer · Heartburn, led by 13 companies.
Drug pageRabeprazole: every studyMany companies study it; this page follows only the 56 they lead. All 105 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisaiits history only | 210 open or running | phase 3since Sep 12, 2005 | Aug 19, 2005 | none ahead |
| Johnson & Johnsonits history only | 150 open or running | phase 4since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Pfizerits history only | 40 open or running | phase 1since Mar 24, 2014 | Mar 24, 2014 | none ahead |
| GlaxoSmithKlineits history only | 30 open or running | phase 4since May 14, 2015 | Sep 26, 2013 | none ahead |
| Viatrisits history only | 30 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| Lomond Therapeuticsits history only | 20 open or running | phase 1since May 1, 2024 | May 1, 2024 | none ahead |
| Torrent Pharmaceuticalsits history only | 20 open or running | phase 1since Nov 15, 2013 | Nov 15, 2013 | none ahead |
| Boehringer Ingelheimits history only | 10 open or running | phase 1since May 16, 2022 | May 16, 2022 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 10 open or running | phase 4since May 20, 2013 | May 20, 2013 | none ahead |
| Genuine Research Center, Egyptits history only | 10 open or running | phase 1since Jun 15, 2015 | Jun 15, 2015 | none ahead |
| Neutec Ar-Ge San ve Tic A.Şits history only | 10 open or running | phase 4since Feb 10, 2016 | Feb 10, 2016 | none ahead |
| PriCara, Unit of Ortho-McNeilits history only | 10 open or running | phase 4since Oct 7, 2005 | Oct 7, 2005 | none ahead |
| Yungjin Pharm.its history only | 10 open or running | phase 1since Jan 7, 2021 | Jan 7, 2021 | none ahead |
Also a collaborator on its studies: Ono Pharmaceutical and Pierre Fabre Laboratories.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 40 studies since Aug 19, 2005.
- Sep 26, 2013GlaxoSmithKline’s first study: phase 1 study in NeoplasmsNew to GlaxoSmithKlineGlaxoSmithKline · NCT01954043 · 23 enrolled · United States, Australia, United Kingdom
- Nov 15, 2013Torrent Pharmaceuticals’ first studies: 2 phase 1 studies in HealthyNew to Torrent PharmaceuticalsTorrent Pharmaceuticals · NCT01990586, NCT01990378
- Mar 24, 2014Phase 3 study in Gastroesophageal RefluxEisai · NCT02135107 · 517 enrolled · Japan
- Mar 24, 2014Pfizer’s first study: phase 1 study in HealthyNew to PfizerPfizer · NCT02097329 · 27 enrolled · United States
- Dec 4, 2014Phase 1 study in HealthyPfizer · NCT02311946 · 60 enrolled · United States
- May 14, 20152 phase 4 studies in Gastrointestinal DiseasesGlaxoSmithKline · NCT02605395, NCT02446483
- Jun 15, 2015Genuine Research Center, Egypt’s first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT02477306 · 60 enrolled · Egypt
- Feb 10, 2016Neutec Ar-Ge San ve Tic A.Ş’s first study: phase 4 study in Gastroesophageal RefluxNew to Neutec Ar-Ge San ve Tic A.ŞNeutec Ar-Ge San ve Tic A.Ş · NCT02689999 · 12 enrolled · Turkey
- Jun 16, 2017Phase 1 study in Healthy VolunteerPfizer · NCT03220191 · 12 enrolled · United States
- Jan 7, 2021Yungjin Pharm.’s first study: phase 1 study in Gastroesophageal RefluxNew to Yungjin Pharm.Yungjin Pharm. · NCT04703868 · 88 enrolled · Korea, Republic of
- May 16, 2022Boehringer Ingelheim’s first study: phase 1 study in HealthyNew to Boehringer IngelheimBoehringer Ingelheim · NCT05380947 · 13 enrolled · Germany
- Jul 1, 2022Phase 1 study in HealthyPfizer · NCT05446142 · 18 enrolled · United States
- May 1, 2024Lomond Therapeutics’ first study: phase 1 study in AMLNew to Lomond TherapeuticsLomond Therapeutics · NCT06399315 · 112 enrolled · Australia
- Jan 16, 2025Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellLomond Therapeutics · NCT06787131 · 104 enrolled · Australia
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
| fexuprazanrule | Daewoong Pharmaceutical | phase 4 | 29 |
Studies
All 56 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06787131Leukemia, Lymphocytic, Chronic, B-Cell · Australia | 1 | Completed | Lomond Therapeutics | Jul 4, 2025 | 104 |
| NCT06399315AML · Australia | 1 | Completed | Lomond Therapeutics | Jun 30, 2025 | 112 |
| NCT05446142Healthy · United States | 1 | Completed | Pfizer | Sep 30, 2022 | 18 |
| NCT05380947Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 13, 2022 | 13 |
| NCT04703868Gastroesophageal Reflux · Korea, Republic of | 1 | Completed | Yungjin Pharm. | Jun 1, 2021 | 88 |
| NCT03220191Healthy Volunteer · United States | 1 | Completed | Pfizer | Sep 3, 2017 | 12 |
| NCT02689999Gastroesophageal Reflux · Turkey | 4 | Completed | Neutec Ar-Ge San ve Tic A.Ş | May 2017 | 12 |
| NCT02477306Healthy · Egypt | 1 | Completed | Genuine Research Center, Egypt | Mar 2014 | 60 |
| NCT02605395Gastrointestinal Diseases · Egypt | 4 | Completed | GlaxoSmithKline | Mar 30, 2014 | 70 |
| NCT02446483Gastrointestinal Diseases · Egypt | 4 | Completed | GlaxoSmithKline | Mar 26, 2014 | 60 |
| NCT02311946Healthy · United States | 1 | Completed | Pfizer | Apr 2015 | 60 |
| NCT02135107Gastroesophageal Reflux · Japan | 3 | Completed | Eisai | May 2016 | 517 |
| NCT02097329Healthy · United States | 1 | Completed | Pfizer | Jun 2014 | 27 |
| NCT01990586Healthy · India | 1 | Completed | Torrent Pharmaceuticals | Sep 2010 | |
| NCT01990378Healthy · India | 1 | Completed | Torrent Pharmaceuticals | Sep 2010 | |
| NCT01954043Neoplasms · United States, Australia, United Kingdom | 1 | Completed | GlaxoSmithKline | Feb 29, 2016 | 23 |
| NCT01860482Esophagitis, Peptic · Korea, Republic of | 4 | Completed | Chong Kun Dang Pharmaceutical | May 2015 | 39 |
| NCT01398410Stomach Ulcer · Japan | 3 | Completed | Eisai | Dec 2013 | 405 |
| NCT01397448Stomach Ulcer · Japan | 3 | Completed | Eisai | Mar 2013 | 472 |
| NCT01241409Healthy | 1 | Completed | Johnson & Johnson | Dec 2010 | 78 |
| NCT01202071Healthy · Japan | 2 | Completed | Eisai | Dec 2010 | 24 |
| NCT01186497Healthy | 1 | Completed | Johnson & Johnson | Nov 2010 | 35 |
| NCT01153659Healthy · United States | 1 | Completed | Eisai | Aug 2010 | 90 |
| NCT01089543Dyspepsia · Japan | 2 | Completed | Eisai | Aug 2011 | 338 |
| NCT01101646Gastroesophageal Reflux · United States | 1 | Completed | Johnson & Johnson | Sep 2008 | 36 |
| NCT01085708Healthy | 1 | Completed | Eisai | May 2010 | 16 |
| NCT01085695Healthy | 1 | Completed | Eisai | May 2010 | 16 |
| NCT01008696Esophagitis, Peptic | 4 | Completed | Johnson & Johnson | Aug 2008 | 217 |
| NCT00992589Gastroesophageal Reflux · United States, Australia, Belgium and more | 3 | Completed | Johnson & Johnson | Nov 2011 | 344 |
| NCT00911534Gastroesophageal Reflux · United States | 3 | Completed | Eisai | Jul 2009 | 305 |
| NCT00855361Gastroesophageal Reflux · United States, Germany, Poland and more | 1 | Completed | Johnson & Johnson | Dec 2011 | 69 |
| NCT00839306Gastroesophageal Reflux · United States | 3 | Completed | Eisai | Aug 2009 | 240 |
| NCT00838526Gastroesophageal Reflux · United States | 3 | Completed | Eisai | Jul 31, 2009 | 240 |
| NCT00787891Gastroesophageal Reflux | 3 | Completed | Johnson & Johnson | Jan 2011 | 127 |
| NCT00770913Esophagitis, Peptic · Japan | 3 | Completed | Eisai | Nov 2009 | 337 |
| NCT00747695Gastroesophageal Reflux | 1 | Completed | Johnson & Johnson | 31 | |
| NCT00747526Gastroesophageal Reflux · United States, Belgium, Brazil and more | 1 | Completed | Johnson & Johnson | Feb 2012 | 51 |
| NCT00658775Gastroesophageal Reflux · United States, Argentina, Australia and more | 3 | Completed | Eisai | Sep 2009 | 1,069 |
| NCT00658632Gastroesophageal Reflux · United States | 3 | Completed | Eisai | Apr 2009 | 1,397 |
| NCT00658528Gastroesophageal Reflux · United States, Argentina, Australia and more | 3 | Completed | Eisai | Sep 2009 | 1,061 |
| NCT00649493Healthy · United States | 1 | Completed | Viatris | Jun 2003 | 72 |
| NCT00649194Healthy · United States | 1 | Completed | Viatris | Aug 2003 | 72 |
| NCT00648349Healthy · United States | 1 | Completed | Viatris | Jun 2003 | 72 |
| NCT00553449Gastroesophageal Reflux | 3 | Completed | Johnson & Johnson | 48 | |
| NCT00464308Gastroesophageal Reflux · Australia | 4 | Completed | Johnson & Johnson | May 2008 | 1,392 |
| NCT00378287Gastroesophageal Reflux | 1 | Completed | Johnson & Johnson | 37 | |
| NCT00236197Heartburn · United States | 3 | Completed | Eisai | Mar 2006 | 619 |
| NCT00236184Heartburn · United States | 3 | Completed | Eisai | Mar 2006 | 629 |
| NCT00237367Gastroesophageal Reflux | 4 | Completed | PriCara, Unit of Ortho-McNeil | 52 | |
| NCT00236392Gastroesophageal Reflux | 3 | Completed | Johnson & Johnson | 422 | |
| NCT00216489Gastroesophageal Reflux | 4 | Completed | Johnson & Johnson | 191 | |
| NCT00216450Helicobacter Infections | 4 | Completed | Johnson & Johnson | 80 | |
| NCT00165841Gastroesophageal Reflux · United States | 2 | Completed | Eisai | Dec 2005 | 200 |
| NCT00165672Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Eisai | Oct 2005 | 26 |
| NCT00165646Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Eisai | Oct 2005 | 288 |
| NCT00132496Gastroesophageal Reflux · United States | 2 | Completed | Eisai | May 2006 | 111 |
How it is read
Names in the registry
- “Rabeprazole”, 15 entries
- “rabeprazole”, 14 entries
- “rabeprazole sodium”, 10 entries
- “E3810”, 8 entries
- “Rabeprazole sodium”, 6 entries
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 25 studies
- Esophagitis, Peptic, 3 studies
- Gastrointestinal Diseases, 2 studies
- Stomach Ulcer, 2 studies
- Heartburn, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.